 |
인쇄하기
취소
|
Boehringer Kore, Yuhan to co-market Twinsta
Boehringer Ingelheim Korea and Yuhan Corp. will jointly promote Twinsta, a combination drug of telmisartan and amlodipine, from November 1 here.
Twinsta is effective and well tolerated in a range of more complex, difficult-to-treat patients as well as in those whose blood pressure (BP) was previously not controlled on monotherapy, according to Boehringer Ingelheim Korea.
“This combination...
Twinsta is effective and well tolerated in a range of more complex, difficult-to-treat patients as well as in those whose blood pressure (BP) was previously not controlled on monotherapy, according to Boehringer Ingelheim Korea.
“This combination...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.